EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter randomized trial comparing meropenem and imipenem/cilastatin in the hospital treatment of community-acquired pneumonia



Multicenter randomized trial comparing meropenem and imipenem/cilastatin in the hospital treatment of community-acquired pneumonia



Drugs under Experimental & Clinical Research 25(6): 243-252



An open, multicenter study with 144 patients, aged between 18 and 94 years, was performed to compare the efficacy and safety of meropenem with imipenem/cilastatin in the hospital treatment of community-acquired pneumonia. Patients were randomized to receive either intravenous meropenem (500 mg every 8 h) or intravenous imipenem/cilastatin (1,000 mg every 12 h). The primary end point was considered to be clinical efficacy and the secondary end points were bacteriological response and safety assessment. At the end of therapy, cure or improvement in signs and symptoms as a satisfactory clinical response was observed in 57 of 64 (89.1%) meropenem-treated patients and in 60 of 66 (90.9%) imipenem/cilastatin patients. The mean duration of treatment was 10 days for meropenem and 9.7 days for imipenem/cilastatin. In patients who were followed up for weeks 2-4, the response was satisfactory (100%) for both treatments. A satisfactory bacteriological response, defined as either presumed or confirmed eradication of all pathogens, was found in eight patients who had received meropenem and in 14 patients who had received imipenem/cilastatin. Response was considered satisfactory in 100% of the meropenem group and in 92.9% of the imipenem/cilastatin group and at follow-up, it was 100% for both treatments. Drug-related adverse events were reported in three (4.2%) meropenem-treated patients and in eight (11.0%) imipenem/cilastatin-treated patients. None of these events was classified as serious. The results of this study show that the clinical and bacteriological efficacy and tolerability of meropenem (500 mg every 8 h) are similar to that of imipenem/cilastatin (1,000 mg every 12 h) in the hospital treatment of community-acquired pneumonia.

(PDF 0-2 workdays service: $29.90)

Accession: 035349914

Download citation: RISBibTeXText



Related references

Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Under Experimental and Clinical Research 25(6): 243-252, 2000

Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs under Experimental and Clinical Research 25(6): 243-252, 1999

Treatment of severe pneumonia in hospitalized patients Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33(0): 235, 1993

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrobial Agents and ChemoTherapy 38(3): 547-557, 1994

Hospitalized patients with community-acquired pneumonia in Hong Kong: A randomized study comparing imipenem/cilastatin and ceftazidime. Respiration 64(3): 224-228, 1997

Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrobial Agents and ChemoTherapy 57(4): 1756-1762, 2013

Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections. German and Austrian Imipenem/Cilastatin Study Group. European Journal of Clinical Microbiology & Infectious Diseases 11(8): 683-692, 1992

Meropenem-monotherapy versus imipenem/cilastatin in the treatment of severe hospital-acquired infections at ICU. Intensive Care Medicine 22(1 Supplement): S149-0, 1996

Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study. Minerva Chirurgica 52(3): 317-326, 1997

Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. Journal of Infection and ChemoTherapy 21(1): 16-22, 2015

Meropenem verus imipenem/cilastatin in the treatment of hospital acquired infection of lower respiratory tract. Zhongguo Kangshengsu Zazhi 30(11): 674-676,681, 2005

Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Critical Care 16(1): R28-R28, 2013

A randomized controlled trial on meropenem versus imipenem/cilastatin in the treatment of bacterial infection. Zhongguo Kangshengsu Zazhi 26(2): 118-122, 2001

Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. Journal of ChemoTherapy 16(4): 362-371, 2004

A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections. Zhonghua Nei Ke Za Zhi 40(9): 589-593, 2002